Muckle-Wells Syndrome (MWS) is a rare, genetic autosomal disease which leads to urticaria, sensorineural deafness, and also leads to amyloidosis. The disease is mainly caused due to mutation of CIAS1 gene, that leads to increased production of interleukin 1B. Due to interaction of IL1B and skin receptors, the inflammation occurs, which leads to fever and rashes. The common symptoms include fevers, chills, deafness, arthritis, and recurrent urticaria.The episode of MWS usually lasts for around 48 hours. The disease belongs to a family of cryopyrin- associated periodic syndromes (CAPS), including 2 other diseases, caused by mutation of CIAS1 gene.
Download exclusive Sample of this report:
Muckle-Wells Syndrome can be diagnosed with the help of study of patient’s symptoms and medical evaluation. In addition, gene testing and NLRP3 mutation study also helps in diagnosis of the disease. Owing to extensive growth in genetic engineering, the market is expected to grow duringthe forecast period 2013 to 2019. The major treatments for MWS includes Rilonacept (for CAPS treatment), anakinra (IL-1 receptor antagonist) and Canakinumab, a monoclonal antibody. In addition to the existing treatments, some new treatments are under pipeline studies.
The market of Muckle-Wells Syndrome is driven by factors such as, extensive R&D activities, technological advancement in research and genetic sciences and growing concern about various genetic disorders. Extensive R&D is one of the major factor, propelling the market growth. Considering the growth perspective, many pharmaceutical and biotechnological leaders are engaged in the development of medications and treatments for this disease. However, low epidemiology, lack of awareness and high cost of R&D and treatment are some of the restraints, expected to impose a threat to the growth of the market.
Some of the major players engaged in development and commercialization of treatments for Muckle-Wells Syndrome includes Novartis AG, Istituto Giannina Gaslini, Regeneron Pharmaceuticals, Inc. and Charite-Universitatsmedizin Berlin amongst others.